LI KANG Business Summary

Li Kang Biomedical Co., Ltd. (6242.TWO) operates a vertically integrated business model specializing in the manufacturing and retail of traditional Chinese medicine (TCM), nutritional supplements, and cosmeceuticals. The company generates revenue through a unique "tourism factory" ecosystem that combines government-certified manufacturing demonstrations with immersive consumer education and direct-to-consumer retail. Primary business segments include tourism factory operations—notably the Li Kang Health and Wellness Tourism Factory in Miaoli and the TCM Industry Culture Museum in Tainan—alongside robust telemarketing services and management consulting for leisure-based industrial sites. In the Taiwanese wellness market, Li Kang competes directly with Jourdeness Group Limited, Grape King Bio, and Sinphar Pharmaceutical, distinguishing itself as a dominant player in the niche intersection of biotechnology and industrial tourism. The leadership team is spearheaded by Chairman and CEO Yu-Xiu Zheng, a licensed pharmacist who holds advanced degrees in Health Management and Industrial Pharmacy from the United States. Zheng, the son of Sheng Chun Tang Pharmaceutical Group founder Cheng Ching-Hsiang, orchestrated the company’s strategic pivot from its legacy 3C cable business (formerly BAFO Technologies) into the biomedical sector in 2014. Under his tenure, Li Kang became the first tourism-factory-focused enterprise to list on the Taipei Exchange. The executive suite includes Spokesperson and Assistant Vice President Chuang Yu-Lin, while the board is heavily influenced by major institutional shareholders such as Sheng Chun Tang Pharmaceutical Industrial Co., Ltd. and Li Kang Biotechnical Co., Ltd. Zheng’s prominence in the regional business community is further evidenced by his role as Chairman of the Yi Zai Association, a premier coalition of Tainan-based industrial leaders.